title: [Atrial fibrillation: choice of the method of pharmacological cardioversion].
abstract: The paper considers circumstances under which it is expedient or not expedient to perform cardioversion in patients with paroxysmal or persistent atrial fibrillation. It contains discussion of benefits, limitations and drawbacks of electrical and pharmacological methods of cardioversion. American College of Cardiology/American Heart Association/European Society of Cardiology Guidelines for the Management of Patients With Atrial Fibrillation are presented. These guidelines suggest amiodarone, dofetilide, ibutilide, propafenone, flecainide, and quinidine as first line therapy because of their proven efficacy. Efficacy of intravenous disopyramide and procainamide in some patients with recent onset atrial fibrillation is recognized with certain reservations. The use of azimilide and dronedarone is considered promising. In Russia nibentan and ethacizine can be also used. Special emphasis is made on the possibility of wide use (including self-administration) of loading doses of oral propafenone for cardioversion in some categories of patients with atrial fibrillation of recent onset.
authors.forename: D V
authors.initials: DV
authors.lastname: Preobrazhenskiĭ
authors.forename: B A
authors.initials: BA
authors.lastname: Sidorenko
authors.forename: V G
authors.initials: VG
authors.lastname: Kiktev
authors.forename: R N
authors.initials: RN
authors.lastname: Sidorov
authors.forename: T A
authors.initials: TA
authors.lastname: Andreĭchenko
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000493:pharmacokinetics*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D003657:Decision Making; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D013810:Therapeutic Equivalency; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents